Post hoc analysis of two trials: after loss of response to subcutaneous infliximab 120 mg every other week, escalation to 240 mg restored response in 85.1% (40/47) with Crohn's disease and 82.3% (51/62) with ulcerative colitis, most within 8 weeks.
Secondary analysisn = 109
Dubinsky et al. Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials